反応手順
5-[(5-Bromopyridin-2-yl)methyl]-2-(2-fluorophenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one (51 mg, 0.11 mmol), 2-dicyclohexylphosphino-2′,4′,6′-tri-iso-propyl-1,1′-biphenyl (16 mg, 0.034 mmol, 0.3 equiv), (2-methylpyridin-3-yl)boronic acid (26 mg, 0.19 mmol, 1.7 equiv), palladium(II) acetate (2.6 mg, 0.011 mmol, 0.1 equiv) and an aqueous solution (0.1 mL) of potassium carbonate (39 mg, 0.28 mmol, 2.5 equiv) were combined in dimethylsulfoxide (0.5 mL) and placed into a preheated oil bath at 85° C. for 90 minutes. The mixture was cooled to ambient temperature, stirred with Quadrapure® (50 mg, 1 wt equiv) for 1 hour, filtered and purified by reverse phase HPLC (80:20 to 5:95; water containing 0.1% trifluoroacetic acid:acetonitrile containing 0.1% trifluoroacetic acid), providing the titled compound: 1H-NMR (500 MHz, d6-DMSO) δ 9.10 (1H, s), 8.57 (1H, d, J=2.1 Hz), 8.55 (1H, d, J=4.6 Hz), 8.21 (1H, dd, J=7.9, 1.4 Hz), 7.96 (1H, dd, J=8.1, 2.4 Hz), 7.84 (1H, d, J=8.7 Hz), 7.80 (1H, br s), 7.72 (1H, d, J=8.3 Hz), 7.65 (1H, ddd, J=8.6, 7.3, 1.5 Hz), 7.61 (1H, td, J=7.8, 1.6 Hz), 7.54 (1H, br t, J=7.6 Hz), 7.48-7.38 (3H, m), 7.34 (1H, td, J=7.6, 1.5 Hz), 5.92 (2H, s), 2.44 (3H, s) ppm; low resolution mass spectrometry (ES+) m/z 462.1709 [(M+H)+; calculated for C28H21FN5O: 462.1725].
